Kim LHY, Saleh C, Whalen-Browne A, et al. - Since the benefits and harms of adding long-acting muscarinic antagonists (LAMAs) to inhaled corticosteroids (ICS) and long-acting β ₂-agonists (LABAs) for moderate to severe asthma remain unknown, researchers sought to systematically synthesize the outcomes and adverse events correlated with triple therapy (ICS, LABA, and LAMA) vs dual therapy (ICS plus LABA) in children and adults with persistent uncontrolled asthma. Twenty randomized clinical trials using 3 LAMA types that recruited 11,894 children and adults (mean age, 52 years [range, 9-71 years]; 57.7% female) were involved. When compared with dual therapy, triple therapy was significantly associated with fewer severe asthma exacerbations and modest improvements in asthma control in children (aged 6 to 18 years) and adults with moderate to severe asthma. There were no significant differences in quality of life or mortality.